Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 7/20 | 0.43 |
| ▸ | EGFR | P00533 | 5/20 | 0.43 |
| ▸ | PPIA | P62937 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | KIF5B | P33176 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | AGER | Q15109 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20529581 | 0.85 | PLA2G7 (0.70) | PLA2G7NPC1PPARGRAB9ANCOR2 | |
| SCHEMBL3529574 | 0.81 | PLA2G7 (0.65) | PLA2G7NPC1PPARGRAB9ANCOR2 | |
| SCHEMBL14669893 | 0.81 | PLA2G7 (0.65) | PLA2G7NPC1PPARGRAB9ANCOR2 | |
| SCHEMBL3044208 | 0.81 | MAPT (0.52) | PLA2G7NPC1RAB9AKDREGFR | |
| SCHEMBL3048427 | 0.81 | PLA2G7 (0.50) | PLA2G7NPC1RAB9AKDRPKM | |
| SCHEMBL3034620 | 0.81 | PLA2G7 (0.50) | PLA2G7PKMMEN1KMT2AADORA2A | |
| SCHEMBL3049191 | 0.81 | SMN1; SMN2 (0.53) | PLA2G7NPC1RAB9AKDRPKM | |
| SCHEMBL3047117 | 0.79 | PLA2G7 (0.48) | PLA2G7NPC1RAB9AKDRPKM | |
| SCHEMBL3529772 | 0.78 | PLA2G7 (0.61) | PLA2G7NPC1PPARGRAB9ANCOR2 | |
| SCHEMBL3038930 | 0.78 | PLA2G7 (0.47) | PLA2G7NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018209-B2 | Compounds and methods for the treatment of viruses and cancer | YALE UNIVERSITY (US) | 2015-04-28 | — | — | US | disclosed |
| US-20100222352-A1 | Compounds and Methods for the Treatment of Viruses and Cancer | YALE UNIVERSITY (US) | 2010-09-02 | — | — | US | disclosed |
| WO-2007038387-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRUSES AND CANCER | YALE UNIVERSITY (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222352-A1 | Compounds and Methods for the Treatment of Viruses and Cancer | RCOR1, RCOR3, CCNT1 | PLA2G7 4400/4885NPC1 769/4885PPARG 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.